Seeking Reimbursement Transparency, Palmetto May Deny Coverage for 'Investigational' Molecular Tests
October 05, 2011
Seeking Reimbursement Transparency, Palmetto May Deny Coverage for 'Investigational' Molecular Tests
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CMS Stance on Reimbursement of Multi-Analyte Algorithm Assays Raises Industry Concerns
September 19, 2012 / Pharmacogenomics Reporter - FDA's Rx/Dx Draft Guidance Urges Simultaneous Development, but Addresses Alternative Scenarios
July 13, 2011 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter - Amgen Presents Data on Vectibix/Chemo Efficacy in Wild-Type KRAS Colorectal Cancer Patients
January 27, 2010 / Pharmacogenomics Reporter - Top 10 Most-Read 'PGx Reporter' Stories of 2009: ACLU/Myriad Suit, BRCA Testing, DTC Genomics, FDA Relabeling Figure Big
January 6, 2010 / Pharmacogenomics Reporter